Chordia Therapeutics,Inc Logo

Chordia Therapeutics,Inc

Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.

190A | T

Overview

Corporate Details

ISIN(s):
JP3283730004
LEI:
Country:
Japan
Address:
藤沢市村岡東2−26−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class anti-cancer drugs. Established in November 2017 as a spin-out from a major pharmaceutical company, its mission is to deliver novel treatments to patients with unmet medical needs. The company focuses on developing a pipeline of small-molecule drug candidates that target RNA deregulation stress, a key factor in cancer development. Chordia Therapeutics operates with a focused R&D model, outsourcing activities such as manufacturing, distribution, and sales to external partners to advance its therapeutic programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 05:00
Registration Form
確認書
Japanese 8.1 KB
2025-11-21 05:00
Annual Report
有価証券報告書-第8期(2024/09/01-2025/08/31)
Japanese 2.6 MB
2025-09-05 08:30
Registration Form
有価証券届出書(参照方式)
Japanese 534.8 KB
2025-05-16 02:45
Major Shareholding Notification
臨時報告書
Japanese 20.2 KB
2025-04-11 04:50
Interim Report
半期報告書-第8期(2024/09/01-2025/08/31)
Japanese 144.4 KB
2025-04-11 04:50
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-12-17 07:30
Registration Form
訂正確認書
Japanese 8.7 KB
2024-11-29 07:37
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB
2024-11-29 07:36
Registration Form
確認書
Japanese 8.1 KB
2024-11-29 07:35
Governance Information
内部統制報告書-第7期(2023/09/01-2024/08/31)
Japanese 21.2 KB
2024-11-29 07:34
Annual Report
有価証券報告書-第7期(2023/09/01-2024/08/31)
Japanese 2.8 MB
2024-07-16 06:55
Quarterly Report
四半期報告書-第7期第3四半期(2024/03/01-2024/05/31)
Japanese 123.4 KB
2024-07-16 06:55
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-06 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-29 04:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB

Automate Your Workflow. Get a real-time feed of all Chordia Therapeutics,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordia Therapeutics,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordia Therapeutics,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KOLON CORPORATION Logo
A holding company for diverse businesses in materials, chemicals, fashion, and life sciences.
South Korea
002020
kt nasmedia Co., Ltd. Logo
An integrated digital marketing platform for data-driven online, mobile, and OOH ad solutions.
South Korea
089600
Kubota Pharmaceutical Holdings Co., Ltd. Logo
Developing ophthalmic drugs and devices to preserve and restore vision for patients globally.
Japan
4596
Kweather Co., Ltd. Logo
Provider of weather data, air quality monitoring, and enterprise climate management solutions.
South Korea
068100
Kymera Therapeutics, Inc. Logo
Fintech firm providing data analytics and market intelligence for investment professionals.
United States of America
KYMR
LABCORP HOLDINGS INC. Logo
Provides diagnostic lab testing and biopharma drug development services for healthcare clients.
United States of America
LH
LAMAR ADVERTISING CO/NEW Logo
A leading OOH advertising REIT with billboards, transit, and airport displays in the US & Canada.
United States of America
LAMR
Larimar Therapeutics, Inc. Logo
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America
LRMR
LEAP THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
Lidds AB Logo
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS

Talk to a Data Expert

Have a question? We'll get back to you promptly.